MichaelYoungjunChoiMD

Hematology • La Jolla, CA

Hematologic Oncology

Associate Professor, Medicine, UC San Diego Sch. of Medicine

Join to view full profile

Dr. Choi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Choi's full profile

Already have an account?

Office
3855 Health Sciences Dr
La Jolla, CA 92093
Phone+1 858-822-0863

Fax+1 858-246-1847

Education & Training

University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
University of California (San Diego) Medical CenterResidency, Internal Medicine, 2005 - 2008
Keck School of Medicine of the University of Southern CaliforniaClass of 2005

Certifications & Licensure

CA State Medical License 2007 - 2026
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Young Investigator Award Tower Cancer Research Foundation, 2012

Clinical Trials

UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia Start of enrollment: 2014 Aug 08
Completed
Phase 1
Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL Start of enrollment: 2016 Jun 01
Terminated
Phase 1
Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome Start of enrollment: 2017 Dec 20
Completed
Phase 1
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib Start of enrollment: 2018 May 01
Active, not recruiting
Phase 1
Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients Start of enrollment: 2021 Sep 02
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

269 citations
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Jeffrey A. Jones, Anthony R. Mato, William G. Wierda, Matthew S. Davids, Michael Y. Choi
The Lancet. Oncology. 2018-01-01
15 citations
Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study.
David J Kuter, Kerry A Rogers, Michael A Boxer, Michael Choi, Richy Agajanian
American Journal of Hematology. 2022-06-01
25 citations
The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model.
Max J. Gordon, Andy Kaempf, Andrea Sitlinger, Geoffrey Shouse, Matthew Mei
Clinical Cancer Research. 2021-06-24

Abstracts/Posters

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated ...
Michael Y. Choi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
Michael Y. Choi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
Michael Y. Choi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicent...
Michael Y. Choi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
High-Level ROR1 and BCL2, Cancer-Stemness, and BCL2 Mutations Associate with Venetoclax Resistance in Chronic Lymphocytic Leukemia
Michael Y. Choi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...
Michael Y. Choi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Phase 1/2 trial of cirmtuzumab and ibrutinib: Planned analysis of phase 1 CLL cohorts.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Oncternal Therapeutics Announces Presentation of Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib at 2019 ASH Annual MeetingDecember 9th, 2019
Oncternal Therapeutics Announces Updated Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with IbrutinibJune 3rd, 2019
Oncternal Therapeutics to Present Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with Ibrutinib at the 2019 American Society of Clinical Oncology Annual MeetingMay 15th, 2019
Join now to see all